|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, our HLA genotyping results are consistent with previous studies reporting a strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN among Koreans.
|
26655481 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA gene frequencies varied in Korea.Screening of HLA-B*58:01 before the use of allopurinol might be needed to anticipate probability of SJS/TEN.
|
26632391 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*15:02 for carbamazepine-induced SJS/TEN and HLA-B*58:01 for allopurinol-induced SCAR), involvement of specific TCR, induction of T-cell-mediated responses (e.g. granulysin, Fas ligand, perforin/granzyme B and T-helper 1/2-associated cytokines) and cell death mechanism (e.g. miR-18a-5p-induced apoptosis; annexin A1 and formyl peptide receptor 1-induced necroptosis in keratinocytes).
|
27154258 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The frequencies of patients who carried the HLA-B*15:02 in the SJS/TEN (12.82%) or the DRESS (9.52%) groups were not significantly different from that of the controls (14.13%).
|
26928377 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A decision tree model was constructed to incorporate the real-world data on AED prescription patterns, incidences of AED-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), costs of AED treatments, SJS/TEN treatment, and HLA-B*15:02 testing, and quality of life.
|
26888992 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B*15:02.
|
27096699 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We developed a novel assay for the detection of the HLA-B*15:02 allele, which is robust, inexpensive and suitable for screening individuals of Asian ancestry in the prevention of CBZ-induced SJS/TEN.
|
27544047 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The identification of subjects carrying the HLA-B*15:02, an inherited allelic variant of the HLA-B gene, and the avoidance of carbamazepine (CBZ) therapy in these subjects are strongly associated with a decrease in the incidence of carbamazepine-induced SJS/TEN.
|
26951484 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Pretherapy screening for HLA-B*59:01 would be useful to reduce the risk of methazolamide-induced SJS/TEN.
|
25918017 |
2016 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Performing HLA-B*1502 genotyping and avoiding carbamazepine in at-risk individuals has been proven to decrease incidences of drug-induced TEN.
|
26319500 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We speculated that Korean individuals expressing the HLA-B*4403 allele may be highly susceptible to lamotrigine-induced SJS/TEN.
|
25327504 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Allopurinol is an efficacious urate-lowering therapy (ULT), but is associated with rare serious adverse drug reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), with higher risk among HLA-B*5801 carriers.
|
26554739 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Associations between HLA and carbamazepine hypersensitivity reactions demonstrate both ethnicity and phenotype specificity; with HLA-B*15:02 associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in South East Asian patients only whilst HLA-A*31:01 is associated with all phenotypes of hypersensitivity in multiple ethnicities.
|
24777842 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study demonstrates the genotype of HLA-B*59:01 in a patient with TEN associated with methazolamide treatment and thus supports the possible correlation between genetic background and methazolamide-associated SJS/TEN.
|
25970075 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Individuals who carried the HLA-B*15:02-C*08:01 haplotype had a 14-fold higher risk for co-trimoxazole-induced SJS/TEN.
|
26086150 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found a statistical association between HLA-B*1502 and lamotrigine-induced SJS/TEN in Han Chinese subjects.
|
25428396 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis.
|
25266342 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found that HLA-B*44:03 was significantly associated with CM-SJS/TEN with SOC in the Indian and Brazilian but not the Korean population, and that HLA-A*02:06 might be weakly associated in the Korean- but not the Indian and Brazilian population.
|
25099678 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Furthermore, the variant allele HLA-B*15:02, encoding human leukocyte antigen, is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment.
|
25099164 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data suggests that HLA-B(∗)1502 is a risk factor for carbamazepine induced SJS/TEN.
|
25305458 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HLA-B*44:03 was also detected as an independent risk allele for CM-, including AR-SJS/TEN with SOC.
|
24781922 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
To assess the association between HLA-B*1502 and carbamazepine (CBZ)-induced SJS/TEN, 13 cases and 26 drug-tolerant controls were analyzed.
|
24394201 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Identification of HLA-B*5801 genotype before prescribing allopurinol offers the possibility of avoiding allopurinol-induced SJS/TEN.
|
24732692 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In contrast, HLA-B*40:01 showed negative association with CBZ-induced SJS/TEN ((Pc=8.3×10(-5); OR (95% CI)=0.22(0.1-0.4)).
|
24268988 |
2014 |
|
Toxic Epidermal Necrolysis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results suggest that HLA-B*15:02 is necessary but is not sufficient to produce SJS/TEN following CBZ treatment among Han individuals from northeastern China.
|
24399721 |
2013 |